Cargando…
Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders
The combination of statins and fibrates in the treatment of lipid abnormalities effectively regulates individual lipid fraction levels. In this study, the screening and assessment of the physicochemical properties of simvastatin-fenofibrate solid dispersions were performed. Fenofibrate and simvastat...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962408/ https://www.ncbi.nlm.nih.gov/pubmed/36839925 http://dx.doi.org/10.3390/pharmaceutics15020603 |
_version_ | 1784895997262954496 |
---|---|
author | Górniak, Agata Czapor-Irzabek, Hanna Złocińska, Adrianna Gawin-Mikołajewicz, Agnieszka Karolewicz, Bożena |
author_facet | Górniak, Agata Czapor-Irzabek, Hanna Złocińska, Adrianna Gawin-Mikołajewicz, Agnieszka Karolewicz, Bożena |
author_sort | Górniak, Agata |
collection | PubMed |
description | The combination of statins and fibrates in the treatment of lipid abnormalities effectively regulates individual lipid fraction levels. In this study, the screening and assessment of the physicochemical properties of simvastatin-fenofibrate solid dispersions were performed. Fenofibrate and simvastatin were processed using the kneading method in different weight ratios, and the resulting solid dispersions were assessed using differential scanning calorimetry (DSC), X-ray powder diffractometry (XRPD), Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), contact angle, as well as dissolution tests. The obtained results confirmed the formation of a simple eutectic phase diagram, with a eutectic point containing 79 wt% fenofibrate and 21 wt% simvastatin, lack of chemical interactions between the ingredients, and simvastatin impact on improving fenofibrate dissolution profile, due to the formation of crystalline solid dispersions by the kneading method. |
format | Online Article Text |
id | pubmed-9962408 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99624082023-02-26 Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders Górniak, Agata Czapor-Irzabek, Hanna Złocińska, Adrianna Gawin-Mikołajewicz, Agnieszka Karolewicz, Bożena Pharmaceutics Article The combination of statins and fibrates in the treatment of lipid abnormalities effectively regulates individual lipid fraction levels. In this study, the screening and assessment of the physicochemical properties of simvastatin-fenofibrate solid dispersions were performed. Fenofibrate and simvastatin were processed using the kneading method in different weight ratios, and the resulting solid dispersions were assessed using differential scanning calorimetry (DSC), X-ray powder diffractometry (XRPD), Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), contact angle, as well as dissolution tests. The obtained results confirmed the formation of a simple eutectic phase diagram, with a eutectic point containing 79 wt% fenofibrate and 21 wt% simvastatin, lack of chemical interactions between the ingredients, and simvastatin impact on improving fenofibrate dissolution profile, due to the formation of crystalline solid dispersions by the kneading method. MDPI 2023-02-10 /pmc/articles/PMC9962408/ /pubmed/36839925 http://dx.doi.org/10.3390/pharmaceutics15020603 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Górniak, Agata Czapor-Irzabek, Hanna Złocińska, Adrianna Gawin-Mikołajewicz, Agnieszka Karolewicz, Bożena Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders |
title | Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders |
title_full | Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders |
title_fullStr | Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders |
title_full_unstemmed | Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders |
title_short | Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders |
title_sort | screening of fenofibrate-simvastatin solid dispersions in the development of fixed-dose formulations for the treatment of lipid disorders |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962408/ https://www.ncbi.nlm.nih.gov/pubmed/36839925 http://dx.doi.org/10.3390/pharmaceutics15020603 |
work_keys_str_mv | AT gorniakagata screeningoffenofibratesimvastatinsoliddispersionsinthedevelopmentoffixeddoseformulationsforthetreatmentoflipiddisorders AT czaporirzabekhanna screeningoffenofibratesimvastatinsoliddispersionsinthedevelopmentoffixeddoseformulationsforthetreatmentoflipiddisorders AT złocinskaadrianna screeningoffenofibratesimvastatinsoliddispersionsinthedevelopmentoffixeddoseformulationsforthetreatmentoflipiddisorders AT gawinmikołajewiczagnieszka screeningoffenofibratesimvastatinsoliddispersionsinthedevelopmentoffixeddoseformulationsforthetreatmentoflipiddisorders AT karolewiczbozena screeningoffenofibratesimvastatinsoliddispersionsinthedevelopmentoffixeddoseformulationsforthetreatmentoflipiddisorders |